Table 3 Comparison between dopaminergic drug responsive fatigue (DDRF) and dopaminergic drug non-responsive fatigue (DDNRF)
From: Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment
Variable | DDRF | DDNRF | p |
|---|---|---|---|
Male (n= 79) | 13 (38.24 %) | 24 (53.33 %) | 0.354 |
Age, y (n= 79) | 59.59 ± 8.89 | 63.64 ± 11.80 | 0.074 |
Onset age, y (n= 79) | 54.24 ± 8.95 | 58.82 ± 11.93 | 0.040* |
Duration of disease (n= 79) | 5.35 ± 3.02 | 4.82 ± 3.24 | 0.276 |
Education, y (n= 79) | 10.03 ± 2.93 | 9.36 ± 4.23 | 0.681 |
LEDD (mg/day) (n= 79) | 473.38 ± 281.42 | 438.26 ± 271.25 | 0.804 |
H-Ystage (n= 79) | 2.15 ± 0.82 | 2.04 ± 0.74 | 0.526 |
UPDRS total (n= 79) | 55.94 ± 21.46 | 52.91 ± 20.22 | 0.674 |
UPDRS I (n= 79) | 4.06 ± 2.15 | 3.87 ± 2.61 | 0.506 |
UPDRS II (n= 79) | 13.00 ± 5.65 | 13.59 ± 6.36 | 0.67 |
UPDRS III (n= 79) | 36.76 ± 15.50 | 33.63 ± 14.67 | 0.362 |
Gait (n= 79) | 5.12 ± 3.15 | 5.26 ± 3.41 | 0.843 |
Tremor (n= 79) | 4.32 ± 4.20 | 320 ± 3.89 | 0.19 |
Rigidity (n= 79) | 7.56 ± 4.59 | 6.20 ± 4.19 | 0.198 |
Bradykinesia (n= 79) | 16.94 ± 7.50 | 16.38 ± 7.47 | 0.741 |
UPDRS IV (n= 79) | 2.11 ± 2.77 | 1.82 ± 2.70 | 0.541 |
HAMD (n= 70) | 7.66 ± 4.51 (N= 32) | 10.66 ± 4.70 (N= 38) | 0.006* |
PDSS (n= 70) | 107.81 ± 25.33 (N= 32) | 97.26 ± 25.98 (N= 38) | 0.073 |
MoCA (n= 79) | 22.47 ± 4.14 | 21.42 ± 4.59 | 0.353 |